Else Driehuis

TL;DR: A pancreatic cancer patient-derived organoid (PDO) library is generated that recapitulates the mutational spectrum and transcriptional subtypes of primary Pancreatic cancer and proposes that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.

TL;DR: This protocol describes a strategy for the generation of 3D prostate organoid cultures from healthy mouse and human prostate cells, metastatic prostate cancer lesions and circulating tumor cells, which is the only one that allows the growth of both the luminal and basal prostatic epithelial lineages.

TL;DR: A biobank of patient-derived pancreatic cancer organoids, characterized by whole-genome DNA sequencing, RNA sequencing, and histology, is described, providing a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.

TL;DR: An overview of the protocols used by different groups to establish organoids from various epithelial tissues and cancers, plus the different protocols subsequently used to test the in vitro therapy sensitivity of these patient-derived organoids are provided.

TL;DR: Conditions for long-term culture of human mucosal organoids derived from head and neck squamous cell carcinoma (HNSCC) are described and responses to therapies both currently used in the treatment of HNSCC and those not used in clinical practice are observed.